
Psychemedics Corporation PMD
Quarterly report 2024-Q3
added 05-16-2026
Psychemedics Corporation Total Current Liabilities 2011-2026 | PMD
Annual Total Current Liabilities Psychemedics Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.71 M | 4.71 M | 5.72 M | 5.83 M | 3.94 M | 5.84 M | 4.06 M | 4.22 M | 4.5 M | 3.56 M | 3.6 M | 2.96 M | 2.08 M | 2.28 M | 2.02 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.84 M | 2.02 M | 3.87 M |
Total Current Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
24.8 M | - | -8.98 % | $ 14.8 K | ||
|
Heska Corporation
HSKA
|
39.6 M | - | - | $ 1.31 B | ||
|
Celcuity
CELC
|
44.2 M | $ 88.78 | -3.99 % | $ 4.15 B | ||
|
Akumin
AKU
|
169 M | - | -17.87 % | $ 25.9 M | ||
|
Co-Diagnostics
CODX
|
3.54 M | $ 5.1 | -11.46 % | $ 6.78 M | ||
|
Fulgent Genetics
FLGT
|
85 M | $ 19.04 | -2.36 % | $ 586 M | ||
|
Castle Biosciences
CSTL
|
68.7 M | $ 21.38 | -1.02 % | $ 620 M | ||
|
Aspira Women's Health
AWH
|
3.46 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
31.2 M | - | -61.36 % | $ 2.46 M | ||
|
Guardant Health
GH
|
303 M | $ 126.94 | -4.6 % | $ 15.9 B | ||
|
Biocept
BIOC
|
5.51 M | - | -13.05 % | $ 7.29 M | ||
|
Interpace Biosciences
IDXG
|
5.1 M | $ 1.79 | 2.29 % | $ 7.92 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
13.8 M | - | - | $ 562 M | ||
|
Illumina
ILMN
|
1.58 B | $ 162.14 | -3.52 % | $ 25.1 B | ||
|
CareDx, Inc
CDNA
|
89.8 M | $ 22.29 | -3.59 % | $ 1.19 B | ||
|
Chembio Diagnostics
CEMI
|
39.3 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
4.05 M | - | - | $ 9.42 M | ||
|
ICON Public Limited Company
ICLR
|
3.2 B | $ 149.1 | -2.42 % | $ 11.7 B | ||
|
HTG Molecular Diagnostics
HTGM
|
8.27 M | - | -20.0 % | $ 1.06 M | ||
|
Lantheus Holdings
LNTH
|
333 M | $ 103.22 | 0.39 % | $ 6.97 B | ||
|
Global Cord Blood Corporation
CO
|
647 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | ||
|
DermTech
DMTK
|
13.4 M | - | -11.32 % | $ 2.94 M | ||
|
NeoGenomics
NEO
|
88.3 M | $ 10.96 | -3.09 % | $ 1.4 B | ||
|
Charles River Laboratories International
CRL
|
1.12 B | $ 183.58 | -1.2 % | $ 9.1 B | ||
|
Natera
NTRA
|
441 M | $ 217.28 | -2.17 % | $ 29.7 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.27 B | - | - | $ 10.7 B | ||
|
Medpace Holdings
MEDP
|
1.34 B | $ 454.91 | -0.82 % | $ 13.1 B | ||
|
Pacific Biosciences of California
PACB
|
72.8 M | $ 1.46 | -10.74 % | $ 438 M | ||
|
Mettler-Toledo International
MTD
|
1.2 B | $ 1 157.67 | -1.93 % | $ 23.9 B | ||
|
Exact Sciences Corporation
EXAS
|
641 M | - | - | $ 19.8 B | ||
|
Myriad Genetics
MYGN
|
134 M | $ 4.65 | -0.85 % | $ 431 M | ||
|
National Research Corporation
NRC
|
36.6 M | $ 19.5 | -1.27 % | $ 436 M | ||
|
Personalis
PSNL
|
39.6 M | $ 11.17 | -7.69 % | $ 997 M | ||
|
Senseonics Holdings
SENS
|
24.3 M | $ 6.78 | -3.28 % | $ 283 M | ||
|
QIAGEN N.V.
QGEN
|
512 M | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
61.4 M | - | - | $ 2.69 B | ||
|
Biomerica
BMRA
|
1.74 M | $ 2.21 | 3.03 % | $ 5.08 M | ||
|
Laboratory Corporation of America Holdings
LH
|
2.82 B | $ 264.33 | 1.23 % | $ 22 B | ||
|
Twist Bioscience Corporation
TWST
|
91.4 M | $ 70.6 | -4.51 % | $ 4.22 B | ||
|
Thermo Fisher Scientific
TMO
|
15.2 B | $ 474.92 | -1.49 % | $ 179 B | ||
|
Motus GI Holdings
MOTS
|
3.27 M | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
174 M | $ 8.96 | -1.81 % | $ 1.94 B | ||
|
Quest Diagnostics Incorporated
DGX
|
2.28 B | $ 200.0 | 1.96 % | $ 22.2 B | ||
|
Invitae Corporation
NVTA
|
108 M | - | - | $ 21.2 M |